IQVIA is a diagnostics & research business based in the US. IQVIA shares (IQV) are listed on the NYSE and all prices are listed in US Dollars. IQVIA employs 87,000 staff and has a trailing 12-month revenue of around $14.7 billion.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $200.98 |
|---|---|
| 52-week range | $165.75 - $241.86 |
| 50-day moving average | $218.99 |
| 200-day moving average | $210.58 |
| Wall St. target price | $250.83 |
| PE ratio | 34.8827 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $5.71 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $200.98 from 2023-09-26
| 1 week (2023-09-20) | -2.16% |
|---|---|
| 1 month (2023-08-25) | -8.23% |
| 3 months (2023-06-27) | -6.37% |
| 6 months (2023-03-24) | 6.71% |
| 1 year (2022-09-23) | N/A |
|---|---|
| 2 years (2021-09-27) | -19.01% |
| 3 years (2020-09-25) | 32.84% |
| 5 years (2018-09-27) | 53.69% |
Valuing IQVIA stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IQVIA's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
| Revenue TTM | $14.7 billion |
|---|---|
| Operating margin TTM | 13.17% |
| Gross profit TTM | $5 billion |
| Return on assets TTM | 4.79% |
| Return on equity TTM | 19.75% |
| Profit margin | 7.47% |
| Book value | $31.39 |
| Market Capitalization | $36.5 billion |
TTM: trailing 12 months
We're not expecting IQVIA to pay a dividend over the next 12 months.
Over the last 12 months, IQVIA's shares have ranged in value from as little as $165.75 up to $241.86. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while IQVIA's is 1.3728. This would suggest that IQVIA's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
IQVIA Holdings Inc. engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and decentralized clinical trials, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services.
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.